A Study of Benralizumab in Patients With Eosinophilic Esophagitis
Study Purpose
The aim of this Phase 3 study is to investigate the use of benralizumab as a treatment for patients with EoE. The effect of doses of benralizumab on EoE histologic signs and symptoms will be assessed over a 52-week treatment period (including a 24-week double-blind placebo-controlled treatment period and a 28-week open-label treatment period). It is proposed that benralizumab will deplete eosinophils from GI tissue(s), improve the symptoms of dysphagia, and improve endoscopy scores as well as other markers of disease activity.
Recruitment Criteria
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
Eligible Ages | 12 Years - 65 Years |
Gender | All |
Inclusion Criteria:
- - Patients 12 to 65 years of age, inclusive, at the time of signing the informed consent or assent (if applicable) form.
- - Documented previous diagnosis of EoE by endoscopy.
- - Must be symptomatic at Visit 1 (screening) and Visit 2 (randomization).
- - May be on background medications for EoE and related treatments during the study as long as the background medications have been stable for at least 4 weeks (8 weeks for PPI) prior to the screening.
- - Negative serum pregnancy test for female patients of childbearing potential at Visit1.
- - Women of childbearing potential must agree to use a highly effective form of birth control (confirmed by the Investigator) from randomization throughout the study duration and within 16 weeks after last dose if IP.
Exclusion Criteria:
- - Other GI disorders such as active Helicobacter pylori infection, history of achalasia, esophageal varices, Crohn's disease, ulcerative colitis, inflammatory bowel disease, or celiac disease.
- - Esophageal stricture that prevents the easy passage of a standard endoscope or any critical esophageal stricture that requires dilation during the run-in period.
- - Esophageal dilation performed within 8 weeks prior to screening.
- - Use of a feeding tube, or not eating solid food daily during the run-in period.
- - Hypereosinophilic syndrome, defined by multiple organ involvement and persistent blood eosinophil count >1500 eos/μL.
- - EGPA vasculitis.
- - Eosinophilic gastritis, gastroenteritis, enteritis, or colitis documented by biopsy.
- - Current malignancy, or history of malignancy with some specific exceptions.
- - History of anaphylaxis to any biologic therapy or vaccine.
- - Current active liver disease: - Chronic stable hepatitis B and C (including positive testing for hepatitis B surface antigen [HBsAg] or hepatitis C antibody), or other stable chronic liver disease are acceptable if patient otherwise meets eligibility criteria.
- - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥3 times the upper limit of normal (ULN), confirmed by repeated testing during the run-in period.
- - Helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent or assent (if applicable) is obtained that has not been treated with or has failed to respond to standard of care therapy.
- - History of known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test.
- - Concomitant use of immunosuppressive medication.
- - Initiation or change of a food-elimination diet regimen or reintroduction of a previously eliminated food group in the 6 weeks prior to start of the run-in period.
- - Currently pregnant, breastfeeding, or lactating women.
Trial Details
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT04543409 |
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 3 |
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
AstraZeneca |
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Marc E. Rothenberg, MD, PhD |
Principal Investigator Affiliation | Children's Hospital Medical Center, Cincinnati |
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
Overall Status | Recruiting |
Countries | Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, United Kingdom, United States |
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Eosinophilic Esophagitis |
Arms
Experimental: Benralizumab
Benralizumab active solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
Placebo Comparator: Placebo
Placebo solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
Interventions
Biological: - Benralizumab
Solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
Biological: - Matching placebo
Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC), 1 mL fill volume
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Recruiting
Address
Research Site
Little Rock, Arkansas, 72202
Status
Not yet recruiting
Address
Research Site
Orange, California, 92868
Status
Recruiting
Address
Research Site
Saint Petersburg, Florida, 33709
Status
Recruiting
Address
Research Site
Atlanta, Georgia, 30322-1013
Status
Not yet recruiting
Address
Research Site
Chicago, Illinois, 60611
Status
Recruiting
Address
Research Site
Normal, Illinois, 61761
Status
Recruiting
Address
Research Site
Park Ridge, Illinois, 60068
Status
Recruiting
Address
Research Site
White Marsh, Maryland, 21162
Status
Not yet recruiting
Address
Research Site
Boston, Massachusetts, 02111
Status
Not yet recruiting
Address
Research Site
Boston, Massachusetts, 02115
Status
Withdrawn
Address
Research Site
Boston, Massachusetts, 02115
Status
Not yet recruiting
Address
Research Site
Rochester, Minnesota, 55905
Status
Not yet recruiting
Address
Research Site
Lincoln, Nebraska, 68505
Status
Recruiting
Address
Research Site
Ocean City, New Jersey, 07712
Status
Not yet recruiting
Address
Research Site
New York, New York, 10029
Status
Recruiting
Address
Research Site
Chapel Hill, North Carolina, 27514
Status
Not yet recruiting
Address
Research Site
Winston-Salem, North Carolina, 27157
Status
Not yet recruiting
Address
Research Site
Cincinnati, Ohio, 45229
Status
Recruiting
Address
Research Site
Philadelphia, Pennsylvania, 19104
Status
Not yet recruiting
Address
Research Site
Dallas, Texas, 75246
Status
Recruiting
Address
Research Site
Murray, Utah, 84107
Status
Not yet recruiting
Address
Research Site
Salt Lake City, Utah, 84132
International Sites
Status
Not yet recruiting
Address
Research Site
Dartmouth, Nova Scotia, B2W 6L4
Status
Not yet recruiting
Address
Research Site
London, Ontario, N6A 5W9
Status
Not yet recruiting
Address
Research Site
Ottawa, Ontario, K1G 6C6
Status
Not yet recruiting
Address
Research Site
Windsor, Ontario, N8X 2G1
Status
Recruiting
Address
Research Site
Dijon Cedex, , 21079
Status
Not yet recruiting
Address
Research Site
Lille Cedex, , 59037
Status
Not yet recruiting
Address
Research Site
Lille, , F-59037
Status
Not yet recruiting
Address
Research Site
Lyon Cedex 03, , 69437
Status
Not yet recruiting
Address
Research Site
Pierre benite, , 69495
Status
Not yet recruiting
Address
Research Site
Suresnes Cedex, , 92151
Status
Recruiting
Address
Research Site
Toulouse Cedex 9, , 31059
Status
Not yet recruiting
Address
Research Site
Berlin, , 10825
Status
Recruiting
Address
Research Site
Frankfurt, , 60590
Status
Recruiting
Address
Research Site
München, , 80337
Status
Recruiting
Address
Research Site
München, , 81675
Status
Recruiting
Address
Research Site
Afula, ,
Status
Recruiting
Address
Research Site
Holon, , 58100
Status
Not yet recruiting
Address
Research Site
Jerusalem, , 91120
Status
Recruiting
Address
Research Site
Kfar-Saba, , 4428164
Status
Recruiting
Address
Research Site
Petach-Tikva, , 4920235
Status
Recruiting
Address
Research Site
Tel Aviv, , 64239
Status
Not yet recruiting
Address
Research Site
Firenze, , 50134
Status
Not yet recruiting
Address
Research Site
Genova, , 16132
Status
Recruiting
Address
Research Site
Napoli, , 80131
Status
Not yet recruiting
Address
Research Site
Pisa, , 56124
Status
Recruiting
Address
Research Site
Rozzano, , 20089
Status
Recruiting
Address
Research Site
Verona, , 37126
Status
Recruiting
Address
Research Site
Chiba-shi, , 260-8677
Status
Recruiting
Address
Research Site
Izumo-shi, , 693-8501
Status
Recruiting
Address
Research Site
Maebashi-shi, , 371-8511
Status
Recruiting
Address
Research Site
Osaka, , 637086
Status
Recruiting
Address
Research Site
Amsterdam, , 1105 AZ
Status
Recruiting
Address
Research Site
Nieuwegein, , 3435 CM
Status
Recruiting
Address
Research Site
Nijmegen, , 6525 GA
Status
Not yet recruiting
Address
Research Site
Gdańsk, , 80-214
Status
Not yet recruiting
Address
Research Site
Knurów, , 44-190
Status
Recruiting
Address
Research Site
Lublin, , 20-582
Status
Recruiting
Address
Research Site
Rzeszow, , 35-302
Status
Recruiting
Address
Research Site
Szczecin, , 71-434
Status
Not yet recruiting
Address
Research Site
Warszawa, , 02-507
Status
Not yet recruiting
Address
Research Site
Warszawa, , 04-141
Status
Not yet recruiting
Address
Research Site
Wrocław, , 50-449
Status
Not yet recruiting
Address
Research Site
Łódź, , 93-338
Status
Not yet recruiting
Address
Research Site
Chelyabinsk, , 454091
Status
Not yet recruiting
Address
Research Site
Moscow, , 105066
Status
Not yet recruiting
Address
Research Site
Moscow, , 119992
Status
Not yet recruiting
Address
Research Site
Omsk, , 644112
Status
Recruiting
Address
Research Site
Badalona, , 08916
Status
Recruiting
Address
Research Site
Barcelona, , 08035
Status
Recruiting
Address
Research Site
Barcelona, , 08036
Status
Recruiting
Address
Research Site
Bilbao (Vizcaya), , 48013
Status
Recruiting
Address
Research Site
Madrid, , 28006
Status
Recruiting
Address
Research Site
Madrid, , 28031
Status
Not yet recruiting
Address
Research Site
Madrid, , 28040
Status
Not yet recruiting
Address
Research Site
Brighton, , BN2 5BE
Status
Not yet recruiting
Address
Research Site
Darlington, , DL3 6HX
Status
Recruiting
Address
Research Site
London, , E1 2AJ
Status
Not yet recruiting
Address
Research Site
London, , SW17 0RE